v3.22.4
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Jun. 30, 2022
Current assets:    
Cash and cash equivalents $ 164,682 $ 172,567
Short-term available-for-sale investments 32,074 74,462
Accounts receivable, less allowance for doubtful accounts of $3,250 and $2,568, respectively 184,763 194,548
Inventories 160,233 141,123
Other current assets 23,431 22,856
Total current assets 565,183 605,556
Property and equipment, net 223,851 223,242
Right of use asset 83,937 65,556
Goodwill 869,589 822,101
Intangible assets, net 567,647 531,522
Other assets 53,194 46,828
Total assets 2,363,401 2,294,805
Current liabilities:    
Trade accounts payable 24,100 33,865
Salaries, wages and related accruals 28,633 61,953
Accrued expenses 16,279 17,886
Contract liabilities 21,812 23,406
Income taxes payable 25,277 13,237
Operating lease liabilities - current 10,975 11,928
Current portion of long-term debt obligations   12,500
Other current liabilities 1,319 1,243
Total current liabilities 128,395 176,018
Deferred income taxes 111,381 98,994
Long-term debt obligations 200,000 243,410
Long-term contingent consideration payable 7,000 5,000
Operating lease liabilities 78,183 58,133
Other long-term liabilities 11,336 12,239
Bio-Techne's Shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 157,093,879 and 156,644,212, respectively(1) 1,571 1,566
Additional paid-in capital(1) 700,684 652,467
Retained earnings(1) 1,199,976 1,122,937
Accumulated other comprehensive loss (75,125) (75,200)
Total Bio-Techne's shareholders' equity 1,827,106 1,701,770
Noncontrolling interest   (759)
Total shareholders' equity 1,827,106 1,701,011
Total liabilities and shareholders' equity $ 2,363,401 $ 2,294,805

Source